Roivant Sciences Ltd. (ROIV) stock
ROIVNasdaqPharmaceutical PreparationsFiscal year ends March 31
$38.71+0.10 (+0.26%)
Close on Nov 17, 2026Market cap $27.96BP/E –Yield –
Roivant Sciences total assets
Total assets on the balance sheet at the end of each period.
Roivant Sciences's total assets was $5.31B at Jun 30, 2026. For fiscal 2025 it was $5.71B, up 5.0% from the year before. The highest annual figure on record is $7.22B in fiscal 2023.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Mar 31, 2026 | $5.71B | +5.0% |
| FY2024 | Mar 31, 2025 | $5.44B | -24.7% |
| FY2023 | Mar 31, 2024 | $7.22B | +202.2% |
| FY2022 | Mar 31, 2023 | $2.39B | -7.6% |
| FY2021 | Mar 31, 2022 | $2.59B | -0.2% |
| FY2020 | Mar 31, 2021 | $2.59B | – |
Quarterly total assets
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026CQ2 2026 | Jun 30, 2026 | $5.31B | +5.4% |
| Q4 FY2025CQ1 2026 | Mar 31, 2026 | $5.71B | +5.0% |
| Q3 FY2025CQ4 2025 | Dec 31, 2025 | $5.23B | -9.8% |
| Q2 FY2025CQ3 2025 | Sep 30, 2025 | $5.06B | -18.4% |
| Q1 FY2025CQ2 2025 | Jun 30, 2025 | $5.03B | -22.5% |
| Q4 FY2024CQ1 2025 | Mar 31, 2025 | $5.44B | -24.7% |
| Q3 FY2024CQ4 2024 | Dec 31, 2024 | $5.79B | -20.8% |
| Q2 FY2024CQ3 2024 | Sep 30, 2024 | $6.21B | +200.5% |
| Q1 FY2024CQ2 2024 | Jun 30, 2024 | $6.50B | +204.0% |
| Q4 FY2023CQ1 2024 | Mar 31, 2024 | $7.22B | +202.2% |
| Q3 FY2023CQ4 2023 | Dec 31, 2023 | $7.31B | +231.9% |
| Q2 FY2023CQ3 2023 | Sep 30, 2023 | $2.07B | -6.8% |
| Q1 FY2023CQ2 2023 | Jun 30, 2023 | $2.14B | -17.8% |
| Q4 FY2022CQ1 2023 | Mar 31, 2023 | $2.39B | -7.6% |
| Q3 FY2022CQ4 2022 | Dec 31, 2022 | $2.20B | -21.3% |
| Q2 FY2022CQ3 2022 | Sep 30, 2022 | $2.22B | -28.6% |
| Q1 FY2022CQ2 2022 | Jun 30, 2022 | $2.60B | +5.9% |
| Q4 FY2021CQ1 2022 | Mar 31, 2022 | $2.59B | -0.2% |
| Q3 FY2021CQ4 2021 | Dec 31, 2021 | $2.80B | – |
| Q2 FY2021CQ3 2021 | Sep 30, 2021 | $3.10B | – |
| Q1 FY2021CQ2 2021 | Jun 30, 2021 | $2.45B | – |
| Q4 FY2020CQ1 2021 | Mar 31, 2021 | $2.59B | – |
See a number that looks wrong?